Life Science Investing Nature Genetics Study Validates Seer's Proteograph Platform as Essential for Turning Genetic Signals Into Reliable Drug Targets and Biomarkers
Life Science Investing RetinalGenix Technologies Contracts with Seer Bio to Explore Early Detection of Neurodegenerative, Systemic, and Retinal Diseases
Life Science Investing Seer Highlights How Proteomics Complements Genomics to Advance Precision Medicine at American Society of Human Genetics 2025
Life Science Investing Seer to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
